Abstract
Infections due to carbapenemase-producing Klebsiella pneumoniae represent an emerging threat due to the high mortality rate and lack of valid antimicrobial combinations, especially when the strain is colistin-resistant. We report a case of bloodstream infection due to pandrug-resistant K. pneumoniae treated successfully with an innovative regimen comprising a combination of colistin plus double carbapenem, along with an in vitro analysis showing the synergistic and bactericidal effect.
Keywords:
Bloodstream infection; Colistin; Double carbapenem; Pan-drug resistant K. pneumoniae.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Proteins / genetics
-
Bacterial Proteins / metabolism
-
Carbapenems / pharmacology
-
Carbapenems / therapeutic use*
-
Colistin / pharmacology
-
Colistin / therapeutic use*
-
Drug Resistance, Multiple, Bacterial / genetics*
-
Drug Synergism
-
Drug Therapy, Combination
-
Female
-
Humans
-
Klebsiella Infections / drug therapy*
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / enzymology
-
Klebsiella pneumoniae / genetics*
-
Microbial Sensitivity Tests
-
beta-Lactam Resistance / genetics*
-
beta-Lactamases / genetics
-
beta-Lactamases / metabolism
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Carbapenems
-
beta-Lactamases
-
carbapenemase
-
Colistin